XML 39 R14.htm IDEA: XBRL DOCUMENT
v3.20.4

Intangible Assets and Goodwill | 12 Months Ended
--- | ---
Jan. 03, 2021
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets and Goodwill | Intangible Assets and Goodwill At the end of fiscal years 2020 and 2019, the gross and net amounts of intangible assets were:
(Dollars in Millions) |  | 2020 |  | 2019
Intangible assets with definite lives: |  |  |  |
Patents and trademarks — gross |  | $ | 39,990 |  |  | 36,634 |
Less accumulated amortization |  | 17,618 |  |  | 13,154 |
Patents and trademarks — net |  | $ | 22,372 |  |  | 23,480 |
Customer relationships and other intangibles — gross |  | $ | 22,898 |  |  | 22,056 |
Less accumulated amortization |  | 10,912 |  |  | 9,462 |
Customer relationships and other intangibles — net* |  | $ | 11,986 |  |  | 12,594 |
Intangible assets with indefinite lives: |  |  |  |
Trademarks |  | $ | 7,195 |  |  | 6,922 |
Purchased in-process research and development(1) |  | 11,849 |  |  | 4,647 |
Total intangible assets with indefinite lives |  | $ | 19,044 |  |  | 11,569 |
Total intangible assets — net |  | $ | 53,402 |  |  | 47,643 |
*The majority is comprised of customer relationships (1) In fiscal year 2020, the Company completed multiple acquisitions and recorded in-process research and development intangible assets of $6.0 billion from Momenta Pharmaceuticals, Inc., $0.8 billion for bermekimab and certain related assets from XBiotech, Inc., and $0.4 billion from the acquisition of all outstanding shares in Verb Surgical, Inc. Goodwill as of January 3, 2021 and December 29, 2019, as allocated by segment of business, was as follows:
(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | Medical Devices |  | Total
Goodwill at December 30, 2018 |  | $ | 8,670 |  |  | 9,063 |  |  | 12,720 |  |  | 30,453 |
Goodwill, related to acquisitions |  | 1,188 |  |  | 75 |  |  | 2,018 |  |  | 3,281 |
Currency translation/other |  | (122) |  |  | 31 |  |  | (4) |  |  | (95) |
Goodwill at December 29, 2019 |  | $ | 9,736 |  |  | 9,169 |  |  | 14,734 |  |  | 33,639 |
Goodwill, related to acquisitions |  | — |  |  | 1,222 |  |  | 238 |  |  | 1,460 |
Currency translation/other |  | 600 |  |  | 618 |  |  | 76 |  |  | 1,294 |
Goodwill at January 3, 2021 |  | $ | 10,336 |  |  | 11,009 |  |  | 15,048 |  |  | 36,393 |
The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in cost of products sold was $4.7 billion, $4.5 billion and $4.4 billion before tax, for the fiscal years ended January 3, 2021, December 29, 2019 and December 30, 2018, respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions) |  |  |  |  |  |
2021 |  | 2022 |  | 2023 |  | 2024 |  | 2025
$4,600 |  | 4,200 |  | 4,100 |  | 3,900 |  | 3,200
See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration